Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission

Documents similaires

• Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia
  par: Francesca A. M. Kinsella, et autres
  Publié: (2024)
• Long‐term remission of TP53‐mutated therapy‐related acute myeloid leukaemia following allogeneic stem cell transplantation in a heart transplant recipient: A case report and literature review
  par: Annie Xiao, et autres
  Publié: (2024)
• Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation
  par: Kendra Sweet, et autres
  Publié: (2024)
• Measurable residual disease‐guided therapy in acute myeloid leukaemia: Practical insights
  par: Boaz Nachmias, et autres
  Publié: (2025)
• Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013–2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy
  par: Takaaki Konuma, et autres
  Publié: (2025)